Novo Nordisk and Eli Lilly Just Got Some Fantastic News
The study used Novo Nordisk's semaglutide to arrive at its results. The news should only cause the market for GLP-1 drugs to grow faster.
The Motley Fool10/16/2026Positive
NVO
Novo Nordisk A/SNYSEHEALTHCAREDRUG MANUFACTURERS - GENERAL
Key Statistics
Market Cap
$171.36B
P/E Ratio
9.14
EPS
$4.25
Beta
0.38
52W High
$61.11
52W Low
$34.15
50-Day MA
$42.71
200-Day MA
$45.07
Dividend Yield
4.63%
Profit Margin
35.30%
Forward P/E
11.83
PEG Ratio
4.32
About Novo Nordisk A/S
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Fundamentals
| Revenue (TTM) | $329.43B |
| Gross Profit (TTM) | $270.09B |
| EBITDA | $173.68B |
| Operating Margin | 42.50% |
| Return on Equity | 59.80% |
| Return on Assets | 18.70% |
| Revenue/Share (TTM) | $74.19 |
| Book Value | $7.48 |
| Price-to-Book | 4.97 |
| Price-to-Sales (TTM) | 0.52 |
| EV/Revenue | 3.671 |
| EV/EBITDA | 8.18 |
| Quarterly Earnings Growth (YoY) | -20.60% |
| Quarterly Revenue Growth (YoY) | 2.10% |
| Shares Outstanding | $3.34B |
| Float | $3.17B |
| % Insiders | 0.00% |
| % Institutions | 9.88% |
Historical Volatility
HV 10-Day
20.46%
HV 20-Day
35.73%
HV 30-Day
33.79%
HV 60-Day
38.89%
HV Rank
20.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($45.81 target)
3
Buy10
Hold1
SellLatest News
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-term pipeline potential.
Zacks Investment Research10/12/2026Negative
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
UBS analyst Michael Yee believes investors prefer Eli Lilly's growth story to Novo Nordisk's turnaround story. Yee sees Novo Nordisk turning its business around, but believes it could take some time.
The Motley Fool10/9/2026Neutral
Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A Premium
Novo Nordisk is rated Buy versus Hold for Eli Lilly, anchored by a compelling valuation discount to big pharma peers. NVO trades at ~11.2x 2027 earnings, a ~26% discount to peer median, despite consensus growth rates in line with peers and a robust yield. The investment case does not require a rerating; ~10% annual returns are achievable if current discounted valuations hold and yield continues.
Seeking Alpha10/8/2026Positive
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.
Zacks Investment Research10/7/2026Positive
Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
Novo Nordisk rose dramatically because investors were excited after it launched the first GLP-1 weight-loss drug. The company lost the lead in the emerging GLP-1 space to Eli Lilly.
The Motley Fool10/7/2026Negative
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks Investment Research10/6/2026Positive
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
NVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.
Zacks Investment Research10/5/2026Positive
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
Novo Nordisk is a leading GLP-1 company, but its portfolio beyond that is limited. Pfizer hasn't entered the GLP-1 race yet, but the company has a diversified business and a long history of success.
The Motley Fool10/4/2026Positive
Novo provides update on the denecimig Biologics License Application (BLA) in the US
Bagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, with or without inhibitors in adults and children, is still ongoing. The FDA has not communicated a new timeline for expected regulatory action on the BLA.
GlobeNewsWire10/2/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NVO and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 10/19/2026